Clinical Approaches to Cannabis Use

——

David M. Weiss, PhD
Assistant Professor, Department of Psychiatry and Behavioral Health
OSU Early Psychosis Intervention Center
The Ohio State University Wexner Medical Center

MedNet21
Center for Continuing Medical Education

THE OHIO STATE UNIVERSITY
WEXNER MEDICAL CENTER

No conflicts of interest to disclose

2

Learning Objectives

1 Increase knowledge on cannabis use (CU) to inform patient care.

2 Distinguish between disordered, hazardous, non-hazardous, and medical use.

3 Learn strategies to engage patients in cannabis cessation/reduction.

Learning Objectives

1 **Understand**

2 **Assess**

3 **Intervene**

Cannabis Background

- Term refers to plant and drug
- Contains 500 identified chemicals including 125 phytocannabinoids
  - Delta-9-tetrahydrocannabinol (THC)
  - Cannabidiol (CBD)
- Processed and sold in a variety of products/forms

Image from Wikimedia Commons:
https://commons.wikimedia.org/wiki/File:Young_cannabis_plant_in_the_vegetative_stage_01.jpg
Gorelick 2023; Connor et al., 2022

Cannabis Usage Trends – Numbers to Know

3rd — Most commonly-used controlled substance after alcohol and tobacco.

20% — Percentage of adults who have used cannabis in the past 12 months. Over 1/4 of adult CU is at daily/near daily use (4.2% of all adults).

18-19 years
16.1 years — Respectively, the median & mean age of initiation of use. Consistent across the globe.

Connor et al. 2021, United Nations World Drug Report 2020 (global data); Jeffers et al. 2021 (US Data); Richmond-Rakerd et al. 2019;

Cannabis Distinctions

Wide-ranging Therapeutic Uses

Cancer, glaucoma, HIV/AIDS, Hep C, Crohn's, Alzheimer's, any chronic condition that involves nausea, seizures, cachexia, muscle spasms

Pharmacological Dependence & Withdrawal

50% experience withdrawal (lacks severe AEs)

Tolerance occurs but psychoactive effects persist

Limited Tx Options

Limited guidance specific to cannabis use disorder

No FDA approved pharmacological tx for CUD

Bridgeman et al., 2017; Connor et al., 2021; Marcoux et al., 2013; Ramaekers et al., 2020, Zamarripa et al., 2022

Legal, Social, and Cultural Changes 1978

US Cannabis Legalization

- Prohibited
- Decriminalized
- CBD Access
- Medical Use Permitted
- Legalized

Created with mapchart.net

Legal, Social, and Cultural Changes 2000

Legal, Social, and Cultural Changes 2016

Legal, Social, and Cultural Changes 2024

US Cannabis
Legalization 2024

- Prohibited
- Decriminalized
- CBD Access
- Medical Use Permitted
- Legalized

Created with mapchart.net

Legal, Social, and Cultural Changes

US Cannabis
Legalization 2024

- Prohibited
- Decriminalized
- CBD Access
- Medical Use Permitted
- Legalized

Created with mapchart.net

Decreasing legal/occupational consequences

Increasing perception that cannabis is harmless

Increasing cannabis potency

- Data from Hasin 2018; ElSohly et al., 2016, 2021; Compton et al., 2016; Waddell 2021

U.S. Trends Over Time

Trends in 30-Day Prevalence among Respondents of Modal Ages 19 through 50, by Age Group

Figure from Patrick et al., 2023 within Monitoring the Future Panel Study annual report.
Montgomery et al., 2022; Bailey et al., 2023; Kerr et al., 2023;   13

Assessing for Disordered Use

Cannabis Effects

Physiologic Signs in Adolescents and Adults	
Tachycardia	Increased BP
Increased respiratory rate	Red eyes
Dry mouth	Increased Appetite
Nystagmus (involuntary eye movement)	Impaired motor coordination
Slurred speech	Vomiting (Cannabinoid Hyperemisis Syndrome)

Sam Wang (2024)

What Constitutes Disordered Use?

	DSM-IV Abuse[a]	DSM-IV Dependence[b]	DSM-5 SUD[c]
Hazardous use (e.g., driving under the influence)	X	–	X
Social/interpersonal problems related to use	X	–	X
Neglected major roles to use	X	–	X
Legal problems	X	–	–
Withdrawal[d]	–	–	X
Tolerance	–	X	X
Used larger amounts/longer	–	X	X
Repeated attempts to quit/control use	–	X	X
Much time spent using	–	X	X
Physical/psychological problems related to use	–	X	X
Activities given up to use	–	X	X
Craving[d]	–	–	X

(≥1 criteria for DSM-IV Abuse; ≥3 criteria for DSM-IV Dependence; ≥2 criteria for DSM-5 SUD)

1. Simplified
2. Adding withdrawal and craving
3. Removing legal

Figure from Hasin 2018; https://creativecommons.org/licenses/by-nc-nd/4.0/

Assessing for Disordered Use

The Cannabis Use Disorder Identification Test - Revised (CUDIT-R)

Have you used any cannabis over the past six months?   Yes_____   No _____

If you answered "Yes" to the previous question, please answer the following questions about your cannabis use. Circle the response that is most correct for you in relation to your cannabis use over the *past six months*.

1. How often do you use cannabis?

Never	Monthly or less	2-4 times a month	2-3 times a week	4+ times a week
0	1	2	3	4

2. How many hours were you "stoned" on a typical day when you had been using cannabis?

Less than 1	1 or 2	3 or 4	5 or 6	7 or more
0	1	2	3	4

3. How often during the past 6 months did you find that you were not able to stop using cannabis once you had started?

Never	Less than monthly	Monthly	Weekly	Daily/almost daily
0	1	2	3	4

4. How often during the past 6 months did you fail to do what was normally expected from you because of using cannabis?

Never	Less than monthly	Monthly	Weekly	Daily or almost daily
0	1	2	3	4

Adamson et al., 2010

Assessing for Disordered Use

5. How often in the past 6 months have you devoted a great deal of your time to getting, using, or recovering from cannabis?

Never	Less than monthly	Monthly	Weekly	Daily/almost daily
0	1	2	3	4

6. How often in the past 6 months have you had a problem with your memory or concentration after using cannabis?

Never	Less than monthly	Monthly	Weekly	Daily or almost daily
0	1	2	3	4

7. How often do you use cannabis in situations that could be physically hazardous, such as driving, operating machinery, or caring for children?

Never	Less than monthly	Monthly	Weekly	Daily/almost daily
0	1	2	3	4

8. Have you ever thought about cutting down, or stopping, your use of cannabis?

Never	Yes, but not in the past 6 months	Yes, during the past 6 months
0	2	4

Scores of 8 or more indicate hazardous cannabis use, while scores of 12 or more indicate a possible cannabis use disorder for which further intervention may be required.

Adamson SJ, Kay-Lambkin FJ, Baker AL, Lewin TJ, Thornton L, Kelly BJ, and Sellman JD. (2010). An Improved Brief Measure of Cannabis Misuse: The Cannabis Use Disorders Identification Test – Revised (CUDIT-R). *Drug and Alcohol Dependence* 110:137-143.

Cannabis Assessment

Ask!

What are the reasons for use?
Recreational vs. Medical (both?)

Treatment Markers

Record method, quantity, potency (if possible) and frequency of use.

Age of Initiation

Younger age (15 or less) reflects increased likelihood of CUD or hazardous use

Connor et al. 2021, Richmond-Rakerd et al. 2019;

Cannabis Use Disorder Trends

1.4%

Prevalence of CUD
Stable rates (2002 – 2019) US NSDUH data

Perceived Treatment Need

Declining over time from 3% to 1%

Treatment Utilization

Declining over time (9% to 3%), lowest usage in 18-25 yr age group

Connor et al. 2021; Askari, Keyes, Mauro, 2021

Hazardous or Risky Cannabis Use

1. Increased risk of psychosis with use of higher potency cannabis

2. Increase in positive symptoms of psychosis in FEP patients who use higher potency cannabis

3. Greater use associated with poorer symptomology in anxiety and mood disorders

4. High potency THC is more likely to be anxiogenic; CBD anxiolytic

Photo by Liz West: https://www.flickr.com/photos/calliope/394371076
Petrelli et al., 2022.; Sharpe et al., 2020; Mammen et al., 2018; Botsford et al. 2020; Marconi et al. 2016


Dual Diagnosis with CUD

9.3 – 14.5	Any Substance Use Disorder	3.9 – 4.7	Psychotic Disorders
7.8 – 10.3	Alcohol Use Disorder	2.5 – 5.0	Bipolar I Disorders
6.2 – 6.6	Tobacco Use Disorder	2.9 – 3.8	Mood Disorders
4.6	Opioid Use Disorder	2.9 – 3.8	Anxiety Disorders
		3.8 – 4.3	PTSD
		3.2 – 4.8	Personality Disorder

Hasin & Walsh 2021

Treatment Approaches to Cannabis Use

CUD Treatment Overview

| Motivational Enhancement Therapy	Cognitive Behavioral Therapy	Contingency Management Therapy
Focus on CU behavior as discrepant from patient goals	Skill-building, relapse prevention	Reinforce/reward cessation behavior

General Principles of Psychosocial Treatment

- Time-limited (8-16 sessions)

- Individual and group formats

- Evidence-based including among individuals with   co-occurring mental health diagnoses

- Meeting people where they are (consideration of harm reduction vs. cessation)

- Includes psychoeducation and understanding patterns of use

- Increasing motivation

- Increasing skill

Steinberg et al., 2005 (SAMSHA publication)

Initial Sessions: Assessment and Psychoeducation

Type of product	Measurement	Example
Dried or fresh cannabis	Percentage (%) or milligrams (mg) per weight of product	THC 0.7% or 7 mg/gram Total THC 14% or 140 mg/gram
Edibles	Per unit or per package	A package with 2 cookies may be labeled as: THC 5 mg per unit, Total THC 5 mg per unit THC 10 mg, Total THC 10 mg per package
Other products (pre-rolls, oils or capsules)	Milligrams (mg) per single unit Milliliter (ml) per dose	THC 2.5 mg/unit, Total THC 2.5 mg/unit THC 10.5 mg/ml, Total THC 10.5 mg/ml

Choose products with lower total THC and an equal or higher amount of total CBD.

Pennypacker et al., 2022; Fischer et al., 2017; Graphics from https://www.ottawapublichealth.ca/

Initial Sessions: Assessment and Psychoeducation

Perceived Susceptibility		Perceived Benefits
Perceived Severity		Perceived Barriers
Cue to Action	Action Likelihood	Self-Efficacy

Health Belief Model from Rosenstock 1966; 1998

Psychoeducation within the Health Belief Model

Perceived Susceptibility

"Given your family mental health history, cannabis use increases your risk of developing a psychotic disorder"

"I know you've mentioned that you're not interested in changing your cannabis use but I want to observe that you've been increasing to near daily use. At this rate, you are at risk of becoming overly reliant or dependent on cannabis."

Health Belief Model from Rosenstock 1966; 1998

Psychoeducation within the Health Belief Model

Perceived Susceptibility

"Given your family mental health history, cannabis use increases your risk of developing a psychotic disorder"

"Given the frequency of your use, I think its possible you may already be dependent on cannabis to go through your day."

Perceived Severity

"From what we know, individuals with major depressive disorder have worse outcomes with regular use of cannabis."

"Becoming too dependent on any substance, even cannabis, may make it feel impossible to do day-to-day activities without it."

Health Belief Model from Rosenstock 1966; 1998

Psychoeducation within the Health Belief Model

Perceived Susceptibility

"Given your family mental health history, cannabis use increases your risk of developing a psychotic disorder"

"Given the frequency of your use, I think its possible you may already be dependent on cannabis to go through your day."

Perceived Severity

"From what we know, others that also have major depressive disorder have worse outcomes with regular use of marjiuana."

"Becoming dependent on any substance, even cannabis, can make it feel impossible to do day-to-day activities without it."

Perceived Benefits

"Cutting down on your use may help with you getting your work done."

"Quitting may make social interactions easier for you over time."

Health Belief Model from Rosenstock 1966; 1998

Psychoeducation within the Health Belief Model

Perceived Susceptibility

"Given your family mental health history, cannabis use increases your risk of developing a psychotic disorder"

"Given the frequency of your use, I think its possible you may already be dependent on cannabis to go through your day."

Perceived Severity

"From what we know, others that also have major depressive disorder have worse outcomes with regular use of marjiuana."

"Becoming dependent on a substance like cannabis may make it feel impossible to do things without it."

Perceived Benefits

"Cutting down on your use may help with you getting your work done."

"Quitting may make social interactions easier for you over time."

Perceived Barriers

"What are some ways you can have fun with your friends without marjiuana?"

"Let's work on finding other ways for you to unwind after a stressful day at school?"

Health Belief Model from Rosenstock 1966; 1998

Psychoeducation within the Health Belief Model

Perceived Susceptibility

"Given your family mental health history, cannabis use increases your risk of developing a psychotic disorder"

"Given the frequency of your use, I think its possible you may already be dependent on cannabis to go through your day."

Perceived Severity

"From what we know, others that also have major depressive disorder have worse outcomes with regular use of marjiuana."

"Becoming dependent on a substance like cannabis may make it feel impossible to do things without it."

Perceived Benefits

"Cutting down on your use may help with you getting your work done."

"Quitting may make social interactions easier for you over time."

Perceived Barriers

"What are some ways you can have fun with your friends without marijuana?"

"Let's work on finding other ways for you to unwind after a stressful day at school?"

Cue to Action

Ask and assess about CU!

Self-Efficacy

Determining ways to increase pt confidence to identify CU goal and plan

Health Belief Model from Rosenstock 1966; 1998

Initial Sessions: Assessment and Psychoeducation

Perceived Susceptibility:
"Given the frequency of your use, you may already be dependent on cannabis."

Perceived Severity:
"Becoming dependent on any substance, even cannabis, may make it feel impossible to do anything without it."

Perceived Benefits:
"Cutting down on your use may help with you getting your work done."

Perceived Barriers:
"Let's work on developing other ways for you to unwind after a stressful day at school?"

Cue to Action:
Ask & Assess!

Action Likelihood

Self-Efficacy:
"If it feels like you couldn't quit if you tried, what if you start by cutting back?"

Health Belief Model from Rosenstock 1966; 1998

Continuing Sessions: Enhancing Motivation & Engagement

Pre-Contemplation

Contemplation

Preparation

Action

Maintenance

1. Assessment and psychoeducation can move people from pre-contemplation, contemplation to later stages.

2. Does not necessarily happen orderly or sequentially.

Prochaska & DiClemente 1982;SAMSHA treatment manual 2005

Continuing Sessions: Enhancing Motivation & Engagement

Pre-Contemplation

Contemplation

Preparation

Action

Maintenance

- **"I'm not interested in stopping or reducing use."**
- **"Weed helps with my [anxiety]. I don't think it is a problem."**
- **"My use is no different from others in my life."**

Prochaska & DiClemente 1982;SAMSHA treatment manual 2005

Continuing Sessions: Enhancing Motivation & Engagement

Pre-Contemplation

Contemplation

Preparation

Action

Maintenance

- "I'm not interested in stopping or reducing use."
- "Weed helps with my [anxiety]. I don't think it is a problem."
- "My use is no different from others in my life."

1. **Acknowledge pt's stance and inform.**
2. **Avoid being argumentative.**
3. **Look for discrepancies, contradictions over time.**

Prochaska & DiClemente 1982;SAMSHA treatment manual 2005

Motivational Interviewing Strategies

Identifying Discrepancies

"You've told me that using pot helps with your anxiety. Yet anxiety seems to be something you've struggled with for quite some time."

"You've mentioned that getting a job is your #1 priority. How do you think your pot use might interfere with that goal?"

Steinberg et al., 2005 (SAMSHA publication)

Continuing Sessions: Enhancing Motivation & Engagement

Pre-Contemplation

Contemplation

Preparation

Action

Maintenance

- **"I enjoy weed but sometimes it makes me feel anxious"**
- **"I don't like that I'm fighting with [family member] about my cannabis use."**

Prochaska & DiClemente 1982;SAMSHA treatment manual 2005

Continuing Sessions: Enhancing Motivation & Engagement

Pre-Contemplation

Contemplation

Preparation

Action

Maintenance

- "I enjoy weed but sometimes it makes me feel anxious"
- "I don't like that I'm fighting with [family member] about my cannabis use."

1. **Validate the insight.**
2. **Inquire about barriers to setting a reduction/cessation goal.**
3. **Enquire about factors to help them decide to make cessation/reduction a goal**

Prochaska & DiClemente 1982;SAMSHA treatment manual 2005

Motivational Interviewing Strategies

Identifying Discrepancies

"You've told me that using pot helps with your anxiety. Yet anxiety seems to be something you've struggled with for quite some time."

"You've mentioned that getting a job is your #1 priority. How do you think your pot use might interfere with that goal?"

Double-sided Reflections

Patient: "I know I get high too much but school started and I just want to have fun with my friends."

Provider: "On the one hand, you're using cannabis to have fun with your friends, but on the other hand, you are thinking you use too often."

Steinberg et al., 2005 (SAMSHA publication)

Continuing Sessions: Enhancing Motivation & Engagement

| Pre-Contemplation |
| Contemplation |
| **Preparation** |
| Action |
| Maintenance |

- "I want to quit (or cut back)."
- "I think I'd like to try to quit."
- "I'd like to stop but I'm not sure where to start."

Prochaska & DiClemente 1982;SAMSHA treatment manual 2005

Continuing Sessions: Enhancing Motivation & Engagement

| Pre-Contemplation |
| Contemplation |
| **Preparation** |
| Action |
| Maintenance |

- "I want to quit (or cut back)."
- "I think I'd like to try to quit."
- "I'd like to stop but I'm not sure where to start."

1. **Concretize goals.**
2. **Create a step-wise plan to help pts move toward goals.**
3. **Skill-building and identifying factors to facilitate goal attainment.**

Prochaska & DiClemente 1982;SAMSHA treatment manual 2005

Motivational Interviewing Strategies

Double-sided Reflections

Patient: "I know I get high too much but school started and I just want to have fun with my friends."

Provider: "On the one hand, you're using to have fun with your friends, but on the other hand, you are thinking you use too often."

Identifying Discrepancies

"You've told me that using pot helps with your anxiety. Yet you seem to have chronic anxiety concerns that do not seem to improve."

"You've mentioned that getting a job is your #1 priority. How do you think your cannabis use might interfere with that goal?"

Eliciting Self-Motivational Statements

**"How does marijuana get in the way of things that are important to you?"**

"What makes you think it's time to change?"

"What do you imagine could happen if you continue to use cannabis at the rate you have been doing?"

"What makes you think you could succeed in quitting if you decided to do so?"

Steinberg et al., 2005 (SAMSHA publication)

Continuing Sessions: Increasing Skill Toward Goal Achievement

Pre-Contemplation

Contemplation

Preparation

Action

Maintenance

- **"I don't think I'm going to be able to cut my use in half by next week."**
- **"I was able to refuse when my friend offered a joint."**
- **"I've been able to get to sleep without marijuana on most nights this week."**

Prochaska & DiClemente 1982;SAMSHA treatment manual 2005

Continuing Sessions: Increasing Skill Toward Goal Achievement

Pre-Contemplation

Contemplation

Preparation

Action

Maintenance

- "I don't think I'll be able to cut down my use by half this week."
- "I was able to refuse when my friend offered a joint."
- "I've been able to get to sleep without marijuana on most nights this week."

1. **Validate and reinforce efforts.**
2. **Troubleshooting. Which strategies work when/how/in what context?**
3. **Skill-building/refinement.**

Prochaska & DiClemente 1982;SAMSHA treatment manual 2005

Cognitive and Behavioral Strategies

- Identify supportive relationships
- Delay decision to use (wait 5-30 minutes)
- Remove cannabis paraphernalia from home
- Identify situations prone to use (and change them)
- Substitution (oral & tactile)

- Develop relaxation techniques
- Distractions
- Developing effective self-talk
- Imagery/Visualization

SAMSHA treatment manual 2005

Continuing Sessions: Increasing Skill Toward Goal Achievement

Pre-Contemplation

Contemplation

Preparation

Action

Maintenance

- "I've done it!"
- "I haven't used any cannabis in two months."

1. **Relapse and response prevention work**
2. **Regularly assessing use within the first year of goal attainment.**

Prochaska & DiClemente 1982;SAMSHA treatment manual 2005

Takeaways

Takeaways

1 Cannabis use rates and cannabis potency continue to increase.

2 Brief assessment tools can inform whether cannabis use is disordered, hazardous, or non-hazardous.

3 Incorporate motivational interviewing and cognitive behavioral strategies into clinical care to increase patient engagement in reduction/cessation goals.

References
On Prevalence/Incidence Trends

Jeffers, A. M., Glantz, S., Byers, A., & Keyhani, S. (2021). Sociodemographic characteristics associated with and prevalence and frequency of cannabis use among adults in the US. *JAMA network open*, *4*(11), e2136571-e2136571.

Livne, O., Malte, C. A., Olfson, M., Wall, M. M., Keyes, K. M., Maynard, C., ... & Hasin, D. S. (2024). Trends in prevalence of cannabis use disorder among US veterans with and without psychiatric disorders between 2005 and 2019. *American journal of psychiatry*, *181*(2), 144-152.

Compton, W. M., Han, B., Jones, C. M., & Blanco, C. (2019). Cannabis use disorders among adults in the United States during a time of increasing use of cannabis. *Drug and alcohol dependence*, *204*, 107468.

Connor, J. P., Stjepanović, D., Le Foll, B., Hoch, E., Budney, A. J., & Hall, W. D. (2021). Cannabis use and cannabis use disorder. *Nature Reviews Disease Primers*, *7*(1), 16.

Rubin-Kahana, D. S., Hassan, A. N., Sanches, M., & Le Foll, B. (2022). Medical cannabis and past-year cannabis use disorder among adult recreational users in the united states: results from a nationally representative sample. *Frontiers in Psychiatry*, *13*, 836908.

Hasin, D., & Walsh, C. (2021). Trends over time in adult cannabis use: a review of recent findings. *Current opinion in psychology*, *38*, 80-85.

Hasin, D. S. (2018). US epidemiology of cannabis use and associated problems. *Neuropsychopharmacology*, *43*(1), 195-212.

References
On Impacts of Legalization

Zellers, S. M., Ross, J. M., Saunders, G. R., Ellingson, J. M., Anderson, J. E., Corley, R. P., ... & Vrieze, S. (2023). Impacts of recreational cannabis legalization on cannabis use: a longitudinal discordant twin study. *Addiction*, *118*(1), 110-118.

Montgomery, B. W., Roberts, M. H., Margerison, C. E., & Anthony, J. C. (2022). Estimating the effects of legalizing recreational cannabis on newly incident cannabis use. *PloS one*, *17*(7), e0271720.

Kim, H. S., & Monte, A. A. (2016). Colorado cannabis legalization and its effect on emergency care. *Annals of emergency medicine*, *68*(1), 71-75.

Bailey, J. A., Tiberio, S. S., Kerr, D. C., Epstein, M., Henry, K. L., & Capaldi, D. M. (2023). Effects of cannabis legalization on adolescent cannabis use across 3 studies. *American journal of preventive medicine*, *64*(3), 361-367.

Kerr, D. C., Levy, N. S., Bae, H., Boustead, A. E., & Martins, S. S. (2023). Cannabis and alcohol use by US young adults, 2008–2019: Changes in prevalence after recreational cannabis legalization. *American journal of preventive medicine*, *65*(6), 983-992.

Weinberger, A. H., Wyka, K., & Goodwin, R. D. (2022). Impact of cannabis legalization in the United States on trends in cannabis use and daily cannabis use among individuals who smoke cigarettes. *Drug and alcohol dependence*, *238*, 109563.

References

On Cannabis Impacts with Mental Health Conditions

Petrilli, K., Ofori, S., Hines, L., Taylor, G., Adams, S., & Freeman, T. P. (2022). Association of cannabis potency with mental ill health and addiction: a systematic review. *The Lancet Psychiatry*, *9*(9), 736-750.

Marconi, A., Di Forti, M., Lewis, C. M., Murray, R. M., & Vassos, E. (2016). Meta-analysis of the association between the level of cannabis use and risk of psychosis. *Schizophrenia bulletin*, *42*(5), 1262-1269.

Botsford, S. L., Yang, S., & George, T. P. (2020). Cannabis and cannabinoids in mood and anxiety disorders: impact on illness onset and course, and assessment of therapeutic potential. *The American journal on addictions*, *29*(1), 9-26.

Mammen, G., Rueda, S., Roerecke, M., Bonato, S., Lev-Ran, S., & Rehm, J. (2018). Association of cannabis with long-term clinical symptoms in anxiety and mood disorders: a systematic review of prospective studies. *The Journal of clinical psychiatry*, *79*(4), 2248.

Sharpe, L., Sinclair, J., Kramer, A., de Manincor, M., & Sarris, J. (2020). Cannabis, a cause for anxiety? A critical appraisal of the anxiogenic and anxiolytic properties. *Journal of translational medicine*, *18*, 1-21.

Ganesh, S., & D'Souza, D. C. (2022). Cannabis and psychosis: Recent epidemiological findings continuing the "causality debate". *American Journal of Psychiatry*, *179*(1), 8-10.

Jefsen, O. H., Erlangsen, A., Nordentoft, M., & Hjorthøj, C. (2023). Cannabis use disorder and subsequent risk of psychotic and nonpsychotic unipolar depression and bipolar disorder. *JAMA psychiatry*, *80*(8), 803-810.

Hasin, D., & Walsh, C. (2020). Cannabis use, cannabis use disorder, and comorbid psychiatric illness: a narrative review. *Journal of Clinical Medicine*, *10*(1), 15.

Morris, P. E., Vargo, L. A., & Buckner, J. D. (2024). Social Anxiety and Cannabis-Related Problems: The Serial Roles of Distress Tolerance and Cannabis Use Motives. *Substance Use & Misuse*, *59*(7), 1133-1140.

References

Cannabis Perceptions and Other Trends

ElSohly, M. A., Chandra, S., Radwan, M., Majumdar, C. G., & Church, J. C. (2021). A comprehensive review of cannabis potency in the United States in the last decade. *Biological Psychiatry: Cognitive Neuroscience and Neuroimaging*, *6*(6), 603-606.

Duan, Z., Kasson, E., Ruchelli, S., Rajamahanty, A., Williams, R., Sridharan, P., ... & Cavazos-Rehg, P. A. (2024). Assessment of online marketing and sales practices among recreational cannabis retailers in Five US Cities. *Cannabis and Cannabinoid Research*, *9*(4), e1075-e1090.

Mennis, J., McKeon, T. P., & Stahler, G. J. (2023). Recreational cannabis legalization alters associations among cannabis use, perception of risk, and cannabis use disorder treatment for adolescents and young adults. *Addictive behaviors*, *138*, 107552.

Cannabis Pharmacodynamics/kinetics

Gorelick, D. A. (2023). Cannabis-related disorders and toxic effects. *New England Journal of Medicine*, *389*(24), 2267-2275.

Zamarripa, C. A., Vandrey, R., & Spindle, T. R. (2022). Factors that impact the pharmacokinetic and pharmacodynamic effects of cannabis: a review of human laboratory studies. *Current Addiction Reports*, *9*(4), 608-621.

Ramaekers, J. G., Mason, N. L., & Theunissen, E. L. (2020). Blunted highs: pharmacodynamic and behavioral models of cannabis tolerance. *European Neuropsychopharmacology*, *36*, 191-205.

Burillo-Putze, G., Richards, J. R., Rodríguez-Jiménez, C., & Sanchez-Agüera, A. (2022). Pharmacological management of cannabinoid hyperemesis syndrome: an update of the clinical literature. *Expert Opinion on Pharmacotherapy*, *23*(6), 693-702.

References
Cannabis Treatment & Guidelines

Steinberg, K.L.; Roffman, R.A.; Carroll, K.M.; McRee, B.; Babor, T.F.; Miller, M.; Kadden, R.; Duresky, D.; and Stephens, R. Brief Counseling for Marijuana Dependence: A Manual for Treating Adults. HHS Publication No. (SMA) 12-4211. Rockville, MD: Center for Substance Abuse Treatment, Substance Abuse and Mental Health Services Administration, 2005.

Trick, L., Butler, K., Bourgault, Z., Vandervoort, J., & Le Foll, B. (2023). Implementation and preliminary evaluation of a 12-week cognitive behavioural and motivational enhancement group therapy for cannabis use disorder. *Substance Abuse: Research and Treatment*, *17*, 11782218231205840.

Fischer, B., Russell, C., Sabioni, P., Van Den Brink, W., Le Foll, B., Hall, W., ... & Room, R. (2017). Lower-risk cannabis use guidelines: a comprehensive update of evidence and recommendations. *American journal of public health*, *107*(8), e1-e12.

Fischer, B., Robinson, T., Bullen, C., Curran, V., Jutras-Aswad, D., Medina-Mora, M. E., ... & Hall, W. (2022). Lower-Risk Cannabis Use Guidelines (LRCUG) for reducing health harms from non-medical cannabis use: A comprehensive evidence and recommendations update. *International Journal of Drug Policy*, *99*, 103381.

Winters, K. C., Mader, J., Budney, A. J., Stanger, C., Knapp, A. A., & Walker, D. D. (2021). Interventions for cannabis use disorder. *Current opinion in psychology*, *38*, 67-74.

Connor, J. P., Stjepanović, D., Budney, A. J., Le Foll, B., & Hall, W. D. (2022). Clinical management of cannabis withdrawal. *Addiction*, *117*(7), 2075-2095.

Brezing, C. A., & Levin, F. R. (2018). The current state of pharmacological treatments for cannabis use disorder and withdrawal. *Neuropsychopharmacology*, *43*(1), 173-194.

Siddiqui, S., Mehta, D., Coles, A., Selby, P., Solmi, M., & Castle, D. (2024). Psychosocial Interventions for Individuals With Comorbid Psychosis and Substance Use Disorders: Systematic Review and Meta-analysis of Randomized Studies. *Schizophrenia Bulletin*, sbae101.

References
Cannabis Treatment & Guidelines continued

Petros, R., Walker, D. D., Pierce, A., & Monroe-DeVita, M. (2023). Scoping review of cannabis-reduction psychosocial interventions and reasons for use among young adults with psychosis. *Journal of Dual Diagnosis*, *19*(2-3), 124-150.

González-Ortega, I., Echeburúa, E., Alberich, S., Bernardo, M., Vieta, E., de Pablo, G. S., & González-Pinto, A. (2022). Cognitive behavioral therapy program for cannabis use cessation in first-episode psychosis patients: a 1-year randomized controlled trial. *International Journal of Environmental Research and Public Health*, *19*(12), 7325.

Lees, R., Hines, L. A., D'Souza, D. C., Stothart, G., Di Forti, M., Hoch, E., & Freeman, T. P. (2021). Psychosocial and pharmacological treatments for cannabis use disorder and mental health comorbidities: a narrative review. *Psychological Medicine*, *51*(3), 353-364.

Petros, R., Walker, D. D., Davis, A., & Monroe-DeVita, M. (2023). Provider intentions to implement cannabis use intervention in first episode psychosis treatment. *Community mental health journal*, *59*(8), 1479-1489.

Zvolensky, M. J., Paulus, D. J., Garey, L., Manning, K., Hogan, J. B., Buckner, J. D., ... & McHugh, R. K. (2018). Perceived barriers for cannabis cessation: Relations to cannabis use problems, withdrawal symptoms, and self-efficacy for quitting. *Addictive behaviors*, *76*, 45-51.